Last reviewed · How we verify
Egg Oral Immunotherapy
Egg Oral Immunotherapy is a Small molecule drug developed by Hugh A Sampson, MD. It is currently in Phase 2 development. Also known as: Egg white solid.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Egg Oral Immunotherapy |
|---|---|
| Also known as | Egg white solid |
| Sponsor | Hugh A Sampson, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Hypersensitivity
- Injection site reaction
- Cough
- Diarrhoea
- Urticaria
- Abdominal pain
- Upper respiratory tract infection
- Nausea
- Pyrexia
- Corona virus infection
- Paresthesia oral
- Anaphylactic reaction
Key clinical trials
- Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or Oral Immunotherapy (PHASE1, PHASE2)
- Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study (PHASE2, PHASE3)
- Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety (NA)
- A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)
- Pancake Oral Immunotherapy For Egg Allergy In Inducing Tolerance (NA)
- Oral Immunotherapy in Young Children With Food Allergy (NA)
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (PHASE3)
- The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Egg Oral Immunotherapy CI brief — competitive landscape report
- Egg Oral Immunotherapy updates RSS · CI watch RSS
- Hugh A Sampson, MD portfolio CI
Frequently asked questions about Egg Oral Immunotherapy
What is Egg Oral Immunotherapy?
Who makes Egg Oral Immunotherapy?
Is Egg Oral Immunotherapy also known as anything else?
What development phase is Egg Oral Immunotherapy in?
What are the side effects of Egg Oral Immunotherapy?
Related
- Manufacturer: Hugh A Sampson, MD — full pipeline
- Also known as: Egg white solid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing